
GSK’s RSV Vaccine, Arexvy, Gains European Approval for Use in All Adults Aged 18 and Older
GSK’s RSV Vaccine, Arexvy, Gains European Approval for Use in All Adults Aged 18 and Older GSK plc today announced that its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine, Arexvy, has been approved by the European Commission* (EC) for use…











